<DOC>
	<DOCNO>NCT00039403</DOCNO>
	<brief_summary>Phase I trial study effectiveness combine UCN-01 gemcitabine treat patient unresectable metastatic pancreatic cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . UCN-01 may help gemcitabine kill cancer cell make tumor cell sensitive drug</brief_summary>
	<brief_title>UCN-01 Gemcitabine Treating Patients With Unresectable Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety toxicity profile UCN-01 give combination gemcitabine patient unresectable metastatic adenocarcinoma pancreas . II . To characterize pharmacokinetic profile gemcitabine UCN-01 give combination correlate various measurement UCN-01 intracellular concentration . III . To determine recommended dos UCN-01 gemcitabine combination use plan subsequent phase II trial . SECONDARY OBJECTIVES : I . To record frequency , extent , duration tumor response . II . To correlate serum alpha-1 acid glycoprotein ( AGP ) level UCN-01 pharmacokinetics toxicity . OUTLINE : This dose-escalation study . Patients receive gemcitabine IV 1-2 hour day 1 8 follow UCN-01 IV 3 hour day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Sequential dose escalation UCN-01 follow sequential dose escalation gemcitabine . Cohorts 3-6 patient receive escalate dos UCN-01 gemcitabine maximum tolerate dose ( MTD ) combination determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , least 6 patient treat recommended phase II dose .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Histologically cytologically confirm unresectable metastatic adenocarcinoma pancreas Unidimensionally measurable disease At least 20 mm conventional technique At least 10 mm spiral CT scan Tumor lesion previously irradiate area consider measurable No known brain metastasis Patients sign symptom CNS metastasis time screen must negative CT scan MRI brain Performance status ECOG 02 Performance status Karnofsky 60100 % More 3 month WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count great 100,000/mm^3 Bilirubin great 1.5 mg/dL ALT AST great 2.5 time upper limit normal Creatinine normal Creatinine clearance least 60 mL/min No prior coronary artery disease No symptomatic cardiac dysfunction No prior myocardial infarction No active angina ( even control medication ) No positive stress test No uncontrolled arrhythmia Left ventricular ejection fraction least 45 % Patients symptom suggestive coronary artery disease arrhythmia must evidence cardiac pathology No symptomatic pulmonary dysfunction Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No prior allergic reaction attribute compound similar chemical biological composition UCN01 study agents No insulindependent diabetes mellitus No concurrent uncontrolled illness No ongoing active infection No concurrent psychiatric illness No active malignancy No solid tumor within past 5 year except neoplasia situ nonmelanomatous skin cancer No social situation would preclude study compliance No concurrent overthecounter biologics No concurrent growth factor first study course At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No 2 prior chemotherapy regimen ( e.g. , gemcitabine and/or experimental agent ) alone combination radiotherapy neoadjuvant adjuvant therapy resectable , unresectable , metastatic disease See Chemotherapy At least 6 week since prior radiotherapy recover Prior radiotherapy direct primary tumor bed allow No prior radiotherapy mediastinum , pelvis , low spine , 20 % bone marrow At least 4 week since prior major surgery At least 4 week since prior investigational agent Concurrent enrollment nontherapy trial ( e.g. , quality life ) allow No concurrent herbal remedy No concurrent treatment another active malignancy No concurrent warfarin anticoagulation No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational commercial anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>